Abbott Laboratories (NYSE:ABT) Relative Strength Index (RSI) is 43.70, with weekly volatility at 1.22% and ATR at 1.82. The ABT stock’s 52-week price range has touched low of $86.16 and a $128.54 high. Intraday shares traded counted 3.08 million, which was 38.2% higher than its 30-day average trading volume of 4.98M. Its shares traded higher over the last trading session, gaining 0.14% on 05/24/21. The shares fell to a low of $117.24 before closing at $117.29. ABT’s previous close was $117.13 while the outstanding shares total 1.78B. The firm has a beta of 0.68, a 12-month trailing P/E ratio of 36.53, and a growth ratio of 2.24.
Investors have identified the Medical Devices company Abbott Laboratories as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $209.59 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Abbott Laboratories (ABT) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For ABT, the company has in raw cash 8.05 billion on their books with 756.0 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 21.82 billion total, with 12.46 billion as their total liabilities.
ABT were able to record 2.24 billion as free cash flow during the 07/21/2021 quarter of the year, this saw their quarterly net cash flow reduce by 1.22 billion. In cash movements, the company had a total of 2.64 billion as operating cash flow.
Potential earnings growth for Abbott Laboratories (ABT)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 07/21/2021 quarter of the year, Abbott Laboratories recorded a total of 10.46 billion in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 26.11% coming in sequential stages and their sales for the 07/21/2021 quarter reducing by -2.34%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 4.4 billion trying to sell their products during the last quarter, with the result yielding a gross income of 6.05 billion. This allows shareholders to hold on to 1.78B with the recently reported earning now reading 1.00 cents per share. This is a figure that compared to analyst’s prediction for their 07/21/2021 (1.32 cents a share).
Having a look at the company’s valuation, the company is expected to record 5.46 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on ABT sounds very interesting.
Is the stock of ABT attractive?
In related news, SENIOR VICE PRESIDENT, Watkin Jared sold 94,576 shares of the company’s stock in a transaction that recorded on Apr 30. The sale was performed at an average price of 119.90, for a total value of 11,339,739. As the sale deal closes, the SENIOR VICE PRESIDENT, Karam Sammy now sold 8,600 shares of the company’s stock, valued at 1,049,200. Also, SENIOR VICE PRESIDENT, BIRD ROGER sold 9,439 shares of the company’s stock in a deal that was recorded on Apr 27. The shares were price at an average price of 122.00 per share, with a total market value of 1,151,558. Following this completion of acquisition, the EXECUTIVE VICE PRESIDENT, Wainer Andrea F now holds 6,200 shares of the company’s stock, valued at 755,098. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.70%.
16 out of 23 analysts covering the stock have rated it a Buy, while 3 have maintained a Hold recommendation on Abbott Laboratories. 1 analysts has assigned a Sell rating on the ABT stock. The 12-month mean consensus price target for the company’s shares has been set at $135.80.